NasdaqGS:IBRXBiotechs
ImmunityBio (IBRX) Is Down 5.6% After New Phase 3 ANKTIVA Lung Cancer Data Release – Has The Bull Case Changed?
Earlier this week at the 2026 ASCO Annual Meeting, ImmunityBio presented new randomized Phase 3 data on its IL-15 receptor agonist ANKTIVA in advanced non-small cell lung cancer and comparative data in BCG-unresponsive non-muscle invasive bladder cancer, expanding the clinical evidence across major solid tumor settings.
The ASCO presentations are important because they provide the first substantial non-small cell lung cancer readout for ANKTIVA and fresh comparative bladder cancer analyses,...